Goldenwell Biotech, Inc.
GWLL
$0.70
-$0.07-9.09%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -31,100.00% | -- | 37,400.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -31,100.00% | -- | 37,400.00% |
| Cost of Revenue | -- | -- | 174,900.00% | -- | -- |
| Gross Profit | -- | -- | -237,100.00% | -- | -- |
| SG&A Expenses | 23.40% | -14.01% | -58.80% | 47.14% | -41.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.40% | -14.01% | 694.40% | 47.14% | -41.25% |
| Operating Income | -23.40% | 14.01% | -959.23% | 71.90% | 41.00% |
| Income Before Tax | -21.78% | 54.29% | -805.09% | 65.37% | 39.28% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.78% | 54.29% | -805.09% | 65.37% | 39.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.78% | 54.29% | -805.09% | 65.37% | 39.28% |
| EBIT | -23.40% | 14.01% | -959.23% | 71.90% | 41.00% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -33.33% | 50.00% | -666.67% | 50.00% | 40.00% |
| Normalized Basic EPS | 0.00% | 0.00% | -650.00% | 0.00% | 33.33% |
| EPS Diluted | -33.33% | 50.00% | -666.67% | 50.00% | 40.00% |
| Normalized Diluted EPS | 0.00% | 0.00% | -650.00% | 0.00% | 33.33% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 2.66% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 2.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |